ID: ALA5267854

Max Phase: Preclinical

Molecular Formula: C39H58O12

Molecular Weight: 718.88

Associated Items:

Representations

Canonical SMILES:  CC(=O)O[C@H]1O[C@]2(C[C@@H](C)[C@H]3[C@H](C[C@@]4(C)[C@@H]5CC[C@H]6C(C)(C)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)CC[C@@]67C[C@@]57C[C@@H](OC(C)=O)[C@]34C)O2)[C@@H]2O[C@]12C

Standard InChI:  InChI=1S/C39H58O12/c1-18-13-39(31-36(8,50-31)32(51-39)47-20(3)41)49-22-14-34(6)24-10-9-23-33(4,5)25(48-30-29(44)28(43)21(42)16-45-30)11-12-37(23)17-38(24,37)15-26(46-19(2)40)35(34,7)27(18)22/h18,21-32,42-44H,9-17H2,1-8H3/t18-,21-,22+,23+,24+,25+,26-,27+,28+,29-,30+,31-,32+,34+,35-,36+,37-,38+,39-/m1/s1

Standard InChI Key:  LVZUZAOYWUUHKP-KBHPJZKOSA-N

Associated Targets(Human)

HCC1806 544 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 718.88Molecular Weight (Monoisotopic): 718.3928AlogP: 3.60#Rotatable Bonds: 4
Polar Surface Area: 162.74Molecular Species: NEUTRALHBA: 12HBD: 3
#RO5 Violations: 2HBA (Lipinski): 12HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.25CX Basic pKa: CX LogP: 3.19CX LogD: 3.19
Aromatic Rings: 0Heavy Atoms: 51QED Weighted: 0.22Np Likeness Score: 3.13

References

1. Zhang H, Chen Y, Huang S, Xiao WW, Qiu MH, Shao LD, Chen CH, Li D..  (2023)  Development of actein derivatives as potent anti-triple negative breast cancer agents.,  89  [PMID:37121522] [10.1016/j.bmcl.2023.129307]

Source